Wall Street analyst estimates for Alkermes plc (ALKS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Valuation Ratios
| P/E Ratio | 112.07 |
| Price / Book | 4.16 |
| Dividend Yield | 0.00% |
Price
| Price | $46.07 |
| Market Cap | $7.7B |
| Exchange | NASDAQ |
| Country | IE |
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ALKS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks